InspireMD (NSPR)
NASDAQ:NSPR
Want to see NSPR full AI Analyst Report?
NSPR Stock Chart & Stats
$1.84
$0.06(2.18%)
At close: 4:00 PM EST
$1.84
$0.06(2.18%)
Day’s Range― - ―
52-Week Range$1.28 - $2.93
Previous CloseN/A
Volume8.46K
Average Volume (3M)102.59K
Market Cap
$63.18M
Enterprise Value$56.47M
Total Cash (Recent Filing)$54.21M
Total Debt (Recent Filing)$2.22M
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
May 19, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding46,801,560
10 Day Avg. Volume68,719
30 Day Avg. Volume102,589
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.37
Price to Sales (P/S)14.56
P/FCF Ratio-3.56
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue6.29
Enterprise Value/Gross Profit21.32
Enterprise Value/Ebitda-1.16
Forecast
1Y Price Target
$5.50Price Target Upside198.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$14.55M
Bulls Say, Bears Say
Bulls Say
Clinical Safety And EfficacyClinical trial results showing very low rates of major complications support the device's safety profile versus existing treatments and could increase clinician confidence.
Innovative Device DesignProprietary MicroNet mesh that traps plaque and reduces embolization offers a distinct clinical advantage and could encourage a shift toward a stent-first treatment approach.
Regulatory Approval And Commercial LaunchFDA premarket approval and an established US commercial launch create a clear pathway for US sales and broader physician adoption.
Bears Say
Commercial Adoption And Procedure VolumeA small number of procedures performed to date signals limited commercial uptake, which could slow revenue growth and delay broader market penetration.
Financial Condition And Funding RiskOngoing GAAP losses and persistent cash burn raise the possibility that additional capital may be required if commercial momentum does not improve.
InspireMD News
NSPR FAQ
What was InspireMD’s price range in the past 12 months?
InspireMD lowest stock price was $1.28 and its highest was $2.93 in the past 12 months.
What is InspireMD’s market cap?
InspireMD’s market cap is $63.18M.
When is InspireMD’s upcoming earnings report date?
InspireMD’s upcoming earnings report date is May 19, 2026 which is in 32 days.
How were InspireMD’s earnings last quarter?
InspireMD released its earnings results on Mar 18, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.193 by $0.053.
Is InspireMD overvalued?
According to Wall Street analysts InspireMD’s price is currently Undervalued.
Does InspireMD pay dividends?
InspireMD does not currently pay dividends.
What is InspireMD’s EPS estimate?
InspireMD’s EPS estimate is -0.18.
How many shares outstanding does InspireMD have?
InspireMD has 46,801,560 shares outstanding.
What happened to InspireMD’s price movement after its last earnings report?
InspireMD reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.193. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of InspireMD?
Currently, no hedge funds are holding shares in NSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InspireMD Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (198.91% Upside)
$5.50 (198.91% Upside)
Insider Transactions
Sold Shares
Worth $99.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.82%
12-Months-Change
Fundamentals
Return on Equity
-116.22%
Trailing 12-Months
Asset Growth
48.28%
Trailing 12-Months
Company Description
InspireMD
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
NSPR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth driven by the successful launch of CGuard Prime in the U.S. and strong international performance. Financially, the company showed improved gross margins and a strengthened cash position due to successful financing. However, increased operating expenses and a higher net loss were noted as challenges. Overall, the positive achievements and growth prospects outweighed the financial challenges.View all NSPR earnings summariesNSPR Stock 12 Month Forecast
Average Price Target
$5.50
▲(198.91% Upside)
Technical Analysis
Anika Therapeutics
―
Apyx Medical
―
EDAP TMS
―
Vivani Medical
―
Xtant Medical Holdings
―